Roche and Biogen Idec discontinue ocrelizumab for RA
This article was originally published in Scrip
Roche and Biogen Idec have discontinued the Phase III development of their humanised anti-CD20 monoclonal antibody ocrelizumab for rheumatoid arthritis (RA) after deciding it has an unfavourable risk:benefit profile.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.